GMP Inspectors Will Scrutinize Adverse Event Reporting Compliance
This article was originally published in The Tan Sheet
Executive Summary
Regular under-reporting of serious adverse event reports has spurred FDA to have its good manufacturing practice inspectors review dietary supplement firms’ AERs and reporting practices, FDA’s Fabricant says. Key compliance issues can tip off the agency that a company may be falling short on reporting.
You may also be interested in...
‘Undeniable Truth’ For US FDA Supplement Programs Director: 'So Much Noncompliance'
ODS Director Steven Tave says violative manufacturing processes and products remain common not because FDA isn’t enforcing its regulations. “I applaud those who stand behind their products, but can you stand with the same conviction behind every product on the market?” he said at regulatory summit organized by trade groups.
FDA Needs To Track Actions Built On Supplement AERs – GAO Report
A GAO report says FDA “may be able to expand” its use of supplement adverse event reports if it can track its use of the data to support actions it takes to protect consumers. The report makes five key recommendations for the agency to improve its approach to AERs.
FDA Needs To Track Actions Built On Supplement AERs – GAO Report
A GAO report says FDA “may be able to expand” its use of supplement adverse event reports if it can track its use of the data to support actions it takes to protect consumers. The report makes five key recommendations for the agency to improve its approach to AERs.